GlaxoSmithKline (NYSE: GSK) is selling its oral penicillin production plant in Bristol, Tenn. To Dr. Reddy’s Laboratories (NYSE: RDY).

The deal also includes rights in the U.S. to a pair of GSK drugs – Augmentin and Amoxil.

GSK keeps rights to the drugs outside the U.S. Financial terms were not disclosed. The deal is expected to close in the first half of next year.

“This sale will enable the facility to continue to provide oral penicillin-containing antibacterial products to meet the needs of patients in the United States, and will allow GSK to focus resources on our newer portfolio of differentiated products,” said Jean-Paul Reynaud, senior vice president for Antibiotics and Emerging Markets Supply at GSK.

GSK maintains its U.S. headquarters in RTP and also operates a drug production plant in Zebulon.

Get the latest news alerts: Follow LTW at Twitter.